Highlights | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.212.130. Please contact the publisher to request reinstatement.
Views 2,219
Citations 0
In This Issue of JAMA Dermatology
September 2014

Highlights

JAMA Dermatol. 2014;150(9):921. doi:10.1001/jamadermatol.2013.6555

Cost control in health care requires a focus on value, or the quality of health outcomes for resources used. Hidradenitis suppurativa (HS) is a disease that lacks coordination of care, defined outcomes, and an understanding of costs. Anecdotally, treatments do not deliver on value. In this cohort cost-identification study, Kirby et al demonstrate that HS affects a younger, predominantly female population who more frequently use high-cost settings such as the emergency department and inpatient care. Educational interventions for patients with HS and nondermatologists may reduce unnecessary high-cost care, and defining meaningful outcome measures for patients may improve the value of health care for patients.

×